Study of APL-9796 for Pulmonary Hypertension with CardioMEMS Monitor
Part of Heart & circulation, Lungs & breathing clinical trials.
This trial tests a study drug called APL-9796 for people with pulmonary hypertension (PH). It may help by using your CardioMEMS monitor to see how well the drug works. You can take part only if you have a CardioMEMS implant and your PH is not too mild or too severe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have been diagnosed with pulmonary hypertension (confirmed by a heart catheterization test in the past).
- Your symptoms from PH fall into WHO Class II or III (i.e., you feel some limits during activity but can still do everyday tasks).
- You already have a CardioMEMS sensor implanted in your lung artery to monitor your heart pressure.
- You have not been in the hospital for PH in the last 3 months.
- You do not have severe kidney disease (estimated GFR above 30).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies an implanted system (the Aria CV Pulmonary Hypertension System) to treat pulmonary arterial hypertension, a serious lung-blood vessel and heart condition. It aims to see whether the device can improve outcomes for people who are still sick despite existing PH medicines.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This study tests whether using a mobile health tool can help people with pulmonary arterial hypertension (PAH) manage their condition in daily life. It’s aimed at adults who are stable on their PAH medicines and can track activity using a wearable device.
This study uses heart imaging tests to better understand pulmonary arterial hypertension (PAH) and predict outcomes. It may help doctors tailor treatment for people with PAH.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This trial tests whether a smartphone app can help adolescents with pulmonary hypertension stay active and improve their health. If you are a teen with stable PH and can use an activity tracker, this study may be a good fit.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.